阿西米尼布用于慢性髓性白血病的高级治疗
Adi Shacham-Abulafia1,2, Yulia Volcheck3, Martin Ellis2,4
1Davidoff Cancer Center, Rabin Medical Center, Institute of Hematology, Petah-Tikva, Israel.
European journal of haematology
|October 21, 2024
概括
阿西米尼布在重度预治疗的慢性髓性白血病 (CML) 患者中显示出显著的疗效和耐受性. 这种新型全抑制剂在现实环境中表现出积极的治疗反应和低耐药率.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿西米尼布是一种新型全抑制剂,向ABL1的myristoyl口袋.
- 它已被批准用于费城染色体阳性慢性阶段慢性髓性白血病 (CML-CP) 患者耐药性或不耐受多重氨酸激酶抑制剂 (TKIs) 或T315I突变.
研究的目的:
- 评估阿司明尼布在重度预治疗的CML-CP患者中的疗效和耐受性.
- 在现实环境中评估治疗反应,毒性,无事件生存 (EFS) 和整体生存 (OS).
主要方法:
- 在以色列接受阿西米尼布治疗的30名CML患者的回顾性分析 (2019年7月至2022年8月).
- 患者接受了前三次TKIs的中位数,其中大多数是由于不耐受性而开始服用阿西米尼布.
- 使用Kaplan-Meier方法来评估治疗反应,毒性,EFS和OS.
主要成果:
- 在以前没有CCyR或MMR的患者中,观察到完全细胞遗传响应 (CCyR) (85%) 和主要分子响应 (MMR) (60%) 的高率.
- 耐药性率低 (10%),尽管基线并发症率高 (73%),但没有报告心血管事件.
- 中位数EFS为47个月;中位数OS没有达到.
结论:
- 阿西米尼布在重度预治疗的CML-CP患者中显示出显著的疗效和良好的耐受性.
- 没有观察到新的心血管事件,这表明可能有利的心血管安全概况.
- 需要进一步的长期研究,以充分阐明阿西米尼布对心血管的影响.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


